NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials
NeuroDerm’s clinical development plan remains on track with its previously announced timelines both in the US and EU. ”> Read More
NeuroDerm Parkinson’s Disease Clinical Data Selected for Two Oral Presentations at the American Academy of Neurology 68th Annual Meeting
An Encore Presentation Will be Given at the Movement Disorders Session Following the Identification of ND0612 Stable Levodopa Plasma Levels as a Critical Advance in the Field of Neuroscience; A Platform Presentation on the Effects of Continuously Delivered Carbidopa on Levodopa Bioavailability Will Also be Presented at the Movement Disorders: Parkinson’s Disease Clinical Trials and Therapeutics Session. ”> Read More